RT Journal Article
SR Electronic
T1 Association of Adenosine Deaminase (ADA) +22 G->A (rs73598374) Genotype in Latino Adult Obese
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266231
DO 10.1101/2021.11.11.21266231
A1 Martiniuk, Frank
A1 Tchou-Wong, Kam-Meng
A1 Chen, Angela
A1 Wong, Alexander H.
A1 Cribb, Esme
A1 Smolenski, Gilbert
A1 Yocum, Kyle
A1 Barangan, Anna
A1 Lo, Kahmun
A1 Watt, Melissa
A1 Fagan, Ian
A1 Nadas, Arthur
A1 O’Koren, Chelsea
A1 Francois, Fritz
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.11.21266231.abstract
AB Obesity is a health burden that currently affects over 13% of the global adult population, consisting of over 650 million adults. Obesity is evaluated based on a body mass index (BMI) scale, which is calculated as weight in kilograms divided by the square of height in meters. Adults with a BMI greater than 30kg/m2 are considered to be obese while adults with a BMI greater than 40kg/m2 are considered morbidly obese. Adenosine deaminase (ADA) is a polymorphic enzyme that plays an important role in both immune functions and the regulation of intracellular and extracellular concentrations of adenosine. Three alleles of the ADA gene (ADA1, ADA2, ADA6) are associated with type 1 diabetes mellitus (DM1). ADA2/6 may increase susceptibility to DM1 in females. Given the evidence linking obesity with DM1, we wanted to determine whether a correlation exists between ADA2 allele and obesity. The ADA2 (+22 G->A, rs73598374) SNP changes the amino acid at position 8 from aspartic acid (Asp8)(D) to asparagine (Asn)(N). In this study, we present significant evidence of association between the ADA2 allele and obesity or BMIs greater than 25 in the Latino adult but not in the Caucasian population and therefore, may be a risk for obesity and its complications such as DM1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of NYU School of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptADAadenosine deaminaseBMIbody mass indexDM1type 1 diabetes mellitusDM2diabetes mellitus type 2SNPsingle nucleotide polymorphismLDL-Clow density lipoprotein cholesterolHDL-Clower levels of high density lipoprotein cholesterolDMSOdimethylsulfoxidedNTPsdeoxyribonucleotide triphosphates